The startup, where patients access cash-pay telehealth and in-person visits, recently added prescription delivery through Truepill. It’s offering a list of generic medications for $5.
Opportunities exist in many areas of the industry, and patients are hungrier than ever for more engaging and humane experiences. For D2C brands that are ready to capitalize on the changing market, the sky’s the limit.
While D2C can enable creativity in customer acquisition and B2B strategies allow for rapid monetization, companies must thoughtfully target consumers, track clinical outcomes, and demonstrate cost-savings.
Covid-19 showed that pharma companies can be nimble and implement changes that prevent processes from weighing down on operations. But which of these operational and strategic changes will stand the test of time and make this year and the future bright for the industry?
The three-year-old digital health startup began trading on the New York Stock Exchange on Thursday. It merged with a subsidiary of Oaktree Capital Management in a deal that valued the company at $1.6 billion.
The Bay Area hearing device-maker planned to raise $141.3 million in an upsized IPO. Its stock started trading on Nasdaq under the ticker “EAR.”